+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs



An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs



Expert Opinion on Drug Discovery 12(6): 625-633



The emergence of antibiotic-resistant and -tolerant bacteria is a major threat to human health. Although efforts for drug discovery are ongoing, conventional bacteria-centered screening strategies have thus far failed to yield new classes of effective antibiotics. Therefore, new paradigms for discovering novel antibiotics are of critical importance. Caenorhabditis elegans, a model organism used for in vivo, offers a promising solution for identification of anti-infective compounds. Areas covered: This review examines the advantages of C. elegans-based high-throughput screening over conventional, bacteria-centered in vitro screens. It discusses major anti-infective compounds identified from large-scale C. elegans-based screens and presents the first clinically-approved drugs, then known bioactive compounds, and finally novel small molecules. Expert opinion: There are clear advantages of using a C. elegans-infection based screening method. A C. elegans-based screen produces an enriched pool of non-toxic, efficacious, potential anti-infectives, covering: conventional antimicrobial agents, immunomodulators, and anti-virulence agents. Although C. elegans-based screens do not denote the mode of action of hit compounds, this can be elucidated in secondary studies by comparing the results to target-based screens, or conducting subsequent target-based screens, including the genetic knock-down of host or bacterial genes.

(PDF emailed within 0-6 h: $19.90)

Accession: 059383763

Download citation: RISBibTeXText

PMID: 28402221

DOI: 10.1080/17460441.2017.1319358


Related references

Drug-drug interactions of anti-infective drugs: utility of fluorescence cyp inhibition assays in drug discovery. Drug Metabolism and Drug Interactions 21(3-4): 163-185, 2006

C. elegans for anti-infective discovery. Current Opinion in Pharmacology 13(5): 769-774, 2014

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Evaluation of New Anti-Infective Drugs for the Treatment of Infective Endocarditis. Clinical Infectious Diseases 15: S89-S95, 1992

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Special Issues in Clinical Trials of New Anti-Infective Drugs for the Treatment of Sexually Transmitted Diseases. Clinical Infectious Diseases 15: S96-S98, 1992

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Evaluation of New Anti-Infective Drugs for the Treatment of Acute Hematogenous Osteomyelitis in Children. Clinical Infectious Diseases 15: S162-S166, 1992

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Evaluation of New Anti-Infective Drugs for the Treatment of Acute Suppurative Arthritis in Children. Clinical Infectious Diseases 15: S172-S176, 1992

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Evaluation of New Anti-Infective Drugs for the Treatment of Febrile Episodes in Neutropenic Patients. Clinical Infectious Diseases 15: S206-S215, 1992

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Evaluation of New Anti-Infective Drugs for the Treatment of Diarrhea Caused by Giardia lamblia. Clinical Infectious Diseases 15: S244-S248, 1992

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Evaluation of New Anti-Infective Drugs for the Treatment of Diarrhea Caused by Entamoeba histolytica. Clinical Infectious Diseases 15: S254-S258, 1992

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Evaluation of New Anti-Infective Drugs for the Treatment of Acute Pelvic Inflammatory Disease. Clinical Infectious Diseases 15: S53-S61, 1992

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Evaluation of New Anti-Infective Drugs for the Treatment of Uncomplicated Gonorrhea in Adults and Adolescents. Clinical Infectious Diseases 15: S123-S130, 1992

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Evaluation of New Anti-Infective Drugs for the Treatment of Genital Infections Due to Herpes Simplex Virus. Clinical Infectious Diseases 15: S99-S107, 1992

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Evaluation of New Anti-Infective Drugs for the Treatment of Disease Caused by Mycobacterium kansasii and Other Mycobacteria. Clinical Infectious Diseases 15: S307-S312, 1992

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Evaluation of New Anti-Infective Drugs for the Treatment of Acute Pelvic Infections in Hospitalized Women. Clinical Infectious Diseases 15: S43-S52, 1992

Supplement 1. Guidelines for the Evaluation of Anti-Infective Drug Products || Evaluation of New Anti-Infective Drugs for the Treatment and Prevention of Infections Caused by the Mycobacterium avium Complex. Clinical Infectious Diseases 15: S296-S306, 1992